SLS (SELLAS Life Sciences Group) EPS without NRI: $-0.23 (TTM As of Mar. 2026)


SLS SELLAS Life Sciences Group Inc SLS
25 GF Score
Price $12.40
! 1 Warning Sign
View Full Analysis

What is SELLAS Life Sciences Group EPS without NRI?

SELLAS Life Sciences Group SLS +17.55% 25 EPS without NRI is $-0.23 as of Mar. 2026. GuruFocus rates SLS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,176 Biotechnology companies, SELLAS Life Sciences Group ranks better than 82.31% on this metric.

SELLAS Life Sciences Group's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.05. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.23.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 46.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 32.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for SELLAS Life Sciences Group's EPS without NRI or its related term are showing as below:

SLS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -81.2   Med: 34   Max: 83.8
Current: 46.5

During the past 13 years, SELLAS Life Sciences Group's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 83.80% per year. The lowest was -81.20% per year. And the median was 34.00% per year.

SLS's 3-Year EPS without NRI Growth Rate is ranked better than
82.31% of 1176 companies
in the Biotechnology industry
Industry Median: 16.8 vs SLS: 46.50

SELLAS Life Sciences Group's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.23.

SELLAS Life Sciences Group's EPS (Basic) for the three months ended in Mar. 2026 was $-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.23.


SELLAS Life Sciences Group  (NAS:SLS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


SELLAS Life Sciences Group EPS without NRI Related Terms


SELLAS Life Sciences Group EPS without NRI Historical Data

* Premium members only.

The historical data trend for SELLAS Life Sciences Group's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group EPS without NRI Chart

SELLAS Life Sciences Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.25 -1.63 -1.34 -0.50 -0.25

SELLAS Life Sciences Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.07 -0.06 -0.05 -0.05

SLS vs SNDX, CAPR, AGIO: EPS without NRI Comparison

For the Biotechnology subindustry, SELLAS Life Sciences Group's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's PE Ratio without NRI falls into.


SLS
25GF Score
SELLAS Life Sciences Group Inc SLS
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SELLAS Life Sciences Group EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.23 mean?
SELLAS Life Sciences Group (SLS) has a EPS without NRI of $-0.23 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on SELLAS Life Sciences Group and its competitors. According to the industry distribution chart, SELLAS Life Sciences Group ranks #208 out of 1176 companies in the Biotechnology industry, placing it in the top 17.7%.
Is SELLAS Life Sciences Group's EPS without NRI too high?
SELLAS Life Sciences Group's current EPS without NRI is $-0.23. Based on the distribution chart, SELLAS Life Sciences Group ranks #208 out of 1176 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's EPS without NRI compare to SNDX and CAPR?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #208 out of 1176 companies for EPS without NRI. This places SELLAS Life Sciences Group in the top 18% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.80, based on 1,176 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current EPS without NRI is $-0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current EPS without NRI of $-0.23. The current EPS without NRI is $-0.23. SELLAS Life Sciences Group's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current EPS without NRI is $-0.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SELLAS Life Sciences Group Business Description

Other Exchanges RXK3:Germany
Address 7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score

Get the complete analysis for SLS

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.40
Price